-+ 0.00%
-+ 0.00%
-+ 0.00%

Nurix Therapeutics Presents Data at AACR 2025 Highlighting Transformative Potential of Proprietary DEL-AI Platform Leveraging Machine Learning To Speed Discovery Of Novel Drugs

Benzinga·04/28/2025 20:02:58
Listen to the news

Nurix's DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company's proprietary DNA encoded library data

Nurix's DEL Foundation Model can accurately predict novel binders to therapeutically relevant targets, including many targets considered undruggable, with the potential to accelerate the discovery of novel drugs

SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today presented data that demonstrate the potential of its DEL Foundation Model to enable the rapid in silico identification of novel binders for a broad range of therapeutically relevant proteins, addressing a key barrier in the discovery and development of small molecule drugs. These results were presented at the American Association of Cancer Research (AACR) Annual Meeting in Chicago, IL, which is being held from April 25-30, 2025.